Last $4.54 USD
Change Today +0.07 / 1.57%
Volume 147.4K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

sciclone pharmaceuticals inc (SCLN) Snapshot

Open
$4.45
Previous Close
$4.47
Day High
$4.59
Day Low
$4.41
52 Week High
08/1/13 - $6.30
52 Week Low
04/15/14 - $4.24
Market Cap
235.9M
Average Volume 10 Days
283.2K
EPS TTM
$0.24
Shares Outstanding
52.0M
EX-Date
--
P/E TM
19.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for SCICLONE PHARMACEUTICALS INC (SCLN)

sciclone pharmaceuticals inc (SCLN) Related Bloomberg News

View More Bloomberg News

sciclone pharmaceuticals inc (SCLN) Related Businessweek News

No Related Businessweek News Found

sciclone pharmaceuticals inc (SCLN) Details

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for the treatment of oncology, infectious diseases, and cardiovascular disorders primarily in the People’s Republic of China. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, Eastern Europe, and the Middle East regions. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets approximately 10 partnered products in China, including Aggrastat, an interventional cardiology product. The company holds license, promotion, distribution, or marketing agreements with various parties for products, including DC Bead, Abstral, Loramyc, and ondansetron RapidFilm. SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.

570 Employees
Last Reported Date: 03/17/14
Founded in 1989

sciclone pharmaceuticals inc (SCLN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $500.0K
Vice President of Internal Audit
Total Annual Compensation: $270.0K
Vice President of Finance and Chief Financial...
Total Annual Compensation: $118.4K
Compensation as of Fiscal Year 2012.

sciclone pharmaceuticals inc (SCLN) Key Developments

SciClone Pharmaceuticals, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 05:00 PM

SciClone Pharmaceuticals, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 05:00 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Wilson W. Cheung, Chief Financial Officer, Principal Accounting Officer and Senior Vice President of Finance.

SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for 2014

SciClone Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total net revenues of $32,734,000 compared to $33,139,000 a year ago. Income from operations was $815,000 compared to $2,509,000 a year ago. Income before provision for income tax was $850,000 compared to $2,487,000 a year ago. Net income was $36,000 or $0.00 per basic and diluted share compared to $1,888,000 or $0.03 per diluted share a year ago. Non-GAAP net income was $4,016,000 or $0.07 per diluted share compared to $2,035,000 or $0.04 per diluted share a year ago. For the year, the company reported total net revenues of $127,058,000 compared to $156,269,000 a year ago. Income from operations was $10,429,000 compared to $6,410,000 a year ago. Income before provision for income tax was $13,206,000 compared to $6,272,000 a year ago. Net income was $10,964,000 or $0.20 per diluted share compared to $9,620,000 or $0.16 per diluted share a year ago. Non-GAAP net income was $23,152,000 or $0.42 per diluted share compared to $37,764,000 or $0.65 per diluted share a year ago. The company anticipates 2014 revenue to be in the range between $130 million and $135 million, and its non-GAAP earnings per share to be in the range between $0.41 and $0.47.

SciClone Pharmaceuticals, Inc., Q4 2013 Earnings Call, Mar 12, 2014

SciClone Pharmaceuticals, Inc., Q4 2013 Earnings Call, Mar 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLN:US $4.54 USD +0.07

SCLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Interpharm Holdings Inc $0.0001 USD 0.00
Momenta Pharmaceuticals Inc $11.10 USD -0.46
OraSure Technologies Inc $6.92 USD +0.25
ProPhase Labs Inc $1.78 USD -0.0899
Sucampo Pharmaceuticals Inc $6.77 USD -0.19
View Industry Companies
 

Industry Analysis

SCLN

Industry Average

Valuation SCLN Industry Range
Price/Earnings 22.7x
Price/Sales 1.9x
Price/Book 1.6x
Price/Cash Flow 21.5x
TEV/Sales 1.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCICLONE PHARMACEUTICALS INC, please visit www.sciclone.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.